

Amendments to the Claims:

This listing of claims will replace all prior versions and listings of claims in the application.

Listing of Claims:

1. (Currently Amended) ~~Use~~ A method for manufacturing a formulation for the prevention or treatment of stress-induced inflammatory disorder comprising providing *Pediococcus pentosaceus* 16:1 (LMG P-20608), *Leuconostoc mesenteriodes* 23-77:1 (LMG P-20607), *Lactobacillus paracasei* subsp *paracasei* F-19 (LMG P-17086), and *Lactobacillus plantarum* 2362 (LMG P-20606) wherein the bacterial strains are in an amount of at least 10^{11} CFU/ml of each of the bacteria and at least four different fibres for ~~the manufacturing of a formulation for the prevention of a stress-induced inflammatory disorder.~~
2. (Currently Amended) ~~Use~~ A method according to claim 1, wherein stress-induced inflammatory disorder is determined as an increase in neutrophils, cytokines, myeloperoxidase and/or accumulation of the oxidation-related malonedialdehyde.
3. (Currently Amended) ~~Use according to any of proceeding claims,~~ A method according to claim 1, wherein the inflammatory disorder is lung inflammation, urinary inflammation, vaginal inflammation, bowel inflammation, stomach inflammation, liver inflammation, muscle inflammation, inflammation of endocrine and reproductive organs, and brain inflammation.
4. (Currently Amended) ~~Use~~ A method according to claim 3, wherein the fibre is selected from the group consisting of beta-glucan, inulin, pectin, resistant starch, cellulose, hemicellulose, arabinoxylans, arabinogalactans, polyfructose, inulin, oligofructans, galacto-oligosacharides, gums, mucilages, pectins, dextrans, maltodextrins, potato dextrans, synthesized carbohydrates, polydextrose, methycellulose and hydroxypropylmethlcellulose.

5. (Currently Amended) ~~Use~~ A method according to claim 1 ~~any of proceeding claims~~, wherein the four fibres are inulin, beta-glucan, pectin and resistant starch.
6. (Currently Amended) ~~Use~~ A method according to claim 5, wherein the fibres are present in an amount of 2.5 g of each fibre.
7. (Currently Amended) ~~Use~~ A method according to claim 4, wherein the fibre is selected from lignin substances from plants selected from the group comprising waxes, cutin, phytate, saponin, suberin and tannins.
8. (Currently Amended) ~~Use~~ A method according to claim 1 ~~any of proceeding claims~~, wherein the formulation further comprises at least one antioxidant, vitamin, mineral, amino acid, peptide or protein.
9. (Currently Amended) ~~Use~~ A method according to claim 1 ~~any of proceeding claims~~, wherein the formulation further comprises glutamine, or a synthetic version thereof.
10. (Currently Amended) ~~Use~~ A method according to claim 1 ~~any of proceeding claims~~, wherein the formulation further comprises one or more therapeutic agents.
11. (Currently Amended) ~~Use~~ A method according to claim 1 ~~any of preceeding claims~~, wherein the formulation is solid or liquid, such as tablet, gel or spray.
12. (Currently Amended) ~~Use of the formulation according to any proceeding claims for the prevention of a~~ A method for treating a mammal suffering from a stress-induced inflammatory disorder, such as an animal or human being comprising applying a formulation to the mammal, the formulation comprising a result of providing *Pediococcus pentosaceus* 16:1 (LMG P-20608), *Leuconostoc mesenteriodes* 23-77:1 (LMG P-20607), *Lactobacillus paracasei* subsp paracasei F-19 (LMG P-17086), and *Lactobacillus plantarum* 2362 (LMG P-20606) wherein the bacterial strains are in an amount of at least 10¹¹ CFU/ml of each of the bacteria and at least four different fibres.
13. (New) A method according to claim 12, wherein the mammal comprising an animal or a human being.